Ruxolitinib As a Salvage Therapy for Acute and Chronic Graft-versus-Host Disease in Children and Young Adults: a single institution experience
View ORCID ProfileMelissa Mavers, Edna Klinger, View ORCID ProfileDavid C Shyr, View ORCID ProfileAmi J Shah, View ORCID ProfileAlice Bertaina, View ORCID ProfileSandeep Soni
doi: https://doi.org/10.1101/2021.10.29.21265670
Melissa Mavers
1Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford CA
2Bass Center for Childhood Cancer and Blood Diseases, Stanford Children’s Health, Palo Alto, CA
MD, PhDEdna Klinger
2Bass Center for Childhood Cancer and Blood Diseases, Stanford Children’s Health, Palo Alto, CA
MSN, FNP-BCDavid C Shyr
1Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford CA
MDAmi J Shah
1Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford CA
MDAlice Bertaina
1Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford CA
2Bass Center for Childhood Cancer and Blood Diseases, Stanford Children’s Health, Palo Alto, CA
MD, PhDSandeep Soni
1Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford CA
3Department of Pediatrics, Division of Bone Marrow Transplant, University of California San Francisco, San Francisco, CA
MDData Availability
All data produced in the present study are available upon reasonable request to the authors, pending appropriate approval for access to clinical data.
Posted October 30, 2021.
Ruxolitinib As a Salvage Therapy for Acute and Chronic Graft-versus-Host Disease in Children and Young Adults: a single institution experience
Melissa Mavers, Edna Klinger, David C Shyr, Ami J Shah, Alice Bertaina, Sandeep Soni
medRxiv 2021.10.29.21265670; doi: https://doi.org/10.1101/2021.10.29.21265670
Ruxolitinib As a Salvage Therapy for Acute and Chronic Graft-versus-Host Disease in Children and Young Adults: a single institution experience
Melissa Mavers, Edna Klinger, David C Shyr, Ami J Shah, Alice Bertaina, Sandeep Soni
medRxiv 2021.10.29.21265670; doi: https://doi.org/10.1101/2021.10.29.21265670
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2318)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11653)
- Forensic Medicine (10)
- Gastroenterology (688)
- Genetic and Genomic Medicine (3656)
- Geriatric Medicine (344)
- Health Economics (625)
- Health Informatics (2341)
- Health Policy (922)
- Hematology (337)
- HIV/AIDS (765)
- Medical Education (362)
- Medical Ethics (102)
- Nephrology (394)
- Neurology (3407)
- Nursing (193)
- Nutrition (512)
- Oncology (1788)
- Ophthalmology (529)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (227)
- Palliative Medicine (66)
- Pathology (442)
- Pediatrics (1015)
- Primary Care Research (411)
- Public and Global Health (6047)
- Radiology and Imaging (1243)
- Respiratory Medicine (816)
- Rheumatology (373)
- Sports Medicine (319)
- Surgery (392)
- Toxicology (50)
- Transplantation (171)
- Urology (144)